Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp

NACompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 18, 2017

Primary Completion Date

April 15, 2018

Study Completion Date

April 15, 2018

Conditions
Type 1 Diabetes Mellitus
Interventions
DEVICE

Tandem t:slim X2 with Control-IQ Technology + Dexcom G6

Subjects will use the Tandem t:slim X2 with Control-IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].

DEVICE

Dexcom CGM G5

"The Dexcom G5 CGM is a subcutaneous glucose sensor that provides an estimate of the prevailing blood glucose concentration approximately every 5 minutes.The Dexcom G5 sensor alerts the user if the prevailing glucose concentration is higher or lower than predetermined thresholds, or if it is changing too fast. In addition, the Share/Follow functionality of the Dexcom G5 allows up to 5 people (followers) to receive in real-time information about the current blood glucose concentration and rate of change.~The Dexcom G5 system will be used by participants and clinical study staff to monitor glucose levels 24h/day during the camp, ensure participants safety, and compute glycemic control outcomes"

DEVICE

Continuous Subcutaneous Insulin Infusion

Subjects will use a subcutaneous pump to deliver insulin and control their glycemia.

Trial Locations (3)

22903

University of Virginia Center for Diabetes Technology, Charlottesville

80045

Barbara Davis Center, University of Colorado, Aurora

94304

Stanford University, Stanford

All Listed Sponsors
collaborator

Tandem Diabetes Care, Inc.

INDUSTRY

collaborator

DexCom, Inc.

INDUSTRY

lead

University of Virginia

OTHER

NCT03369067 - Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp | Biotech Hunter | Biotech Hunter